Ironwood Pharmaceuticals Appoints Tammi Gaskins as CEO

Current CEO Tom McCourt will retire from his role on the same date but will continue to serve on the company’s Board of Directors.

Tammi has been part of Ironwood’s commercial leadership team since joining the company in 2020. She played a key role in making LINZESS the most prescribed brand in the US for treating irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Read More:Opsin Secures $21M in Funding Led by SYN Ventures

She has also led commercial development for apraglutide, a potential once-weekly treatment for adults with short bowel syndrome with intestinal failure. The drug is currently in Phase 3 development. Before joining Ironwood, Tammi spent 20 years at AstraZeneca, where she held several commercial leadership roles.

Tom joined Ironwood as its first Chief Commercial Officer and helped shape LINZESS’s clinical and commercial strategy. He built the company’s commercial team and worked with partners to grow LINZESS into a blockbuster drug.

After becoming CEO in 2021, Tom led Ironwood’s acquisition of VectivBio, adding apraglutide to its late-stage drug development pipeline. Before joining Ironwood, Tom worked on the commercial and drug development of several leading medicines at Merck, AstraZeneca, Novartis and Amgen.

“It is an honor to be named Ironwood’s next CEO, and I would like to thank Tom and the Board of Directors for their leadership and support,” said Gaskins. “I am excited to continue working with our talented team to bring innovation to patients living with GI and rare diseases.

Tammi was instrumental in driving the turnaround of LINZESS® this year, returning it to blockbuster status and growth. She is uniquely positioned to build upon the strong momentum Ironwood has delivered so far in 2026, and to lead the company through its next phase of growth,” said Julie McHugh, Chair of the Ironwood Board of Directors.

About Ironwood Pharmaceuticals

Founded in 1998, Ironwood Pharmaceuticals develops treatments for people living with gastrointestinal and rare diseases. The company is also developing apraglutide, a long-acting synthetic GLP-2 drug for patients with short bowel syndrome who depend on nutritional support through a vein.

Read More:Syncra Announces Partnership with Neumetry Medical